

Manuela Schmidinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3624872/publications.pdf>

Version: 2024-02-01

93
papers

7,431
citations

377584

21
h-index

84171

75
g-index

93
all docs

93
docs citations

93
times ranked

8673
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2022, 32, 61-68. | 0.9 | 7 |
| 2 | Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. <i>World Journal of Urology</i> , 2022, 40, 747-754. | 1.2 | 4 |
| 3 | Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , 2022, 61, 52-57. | 0.8 | 0 |
| 4 | Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. <i>European Urology Oncology</i> , 2022, 5, 120-124. | 2.6 | 6 |
| 5 | CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. <i>Future Oncology</i> , 2022, 18, 915-926. | 1.1 | 11 |
| 6 | Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 367-367. | 0.8 | 0 |
| 7 | Recent pharmacological approaches for the treatment of renal cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 187-195. | 1.3 | 1 |
| 8 | Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938. | 0.8 | 33 |
| 9 | The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720. | 1.7 | 13 |
| 10 | Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725. | 1.0 | 10 |
| 11 | Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. <i>Annals of Medicine</i> , 2022, 54, 1339-1349. | 1.5 | 8 |
| 12 | Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 265-273. | 2.0 | 44 |
| 13 | The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 79, 783-792. | 0.9 | 46 |
| 14 | Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021, 39, 302-302. | 0.8 | 5 |
| 15 | CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma. <i>BJU International</i> , 2021, 128, 29-32. | 1.3 | 6 |
| 16 | Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021, 39, 301-301. | 0.8 | 9 |
| 17 | What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. <i>Current Opinion in Urology</i> , 2021, 31, 276-284. | 0.9 | 7 |
| 18 | Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2021, 31, 270-275. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 755-765. | 2.6 | 100 |
| 20 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300. Reply to Johanna Neely, Olivier Himmelfarb, and François Goldwasser's™s Letter to the Editor re: Keiichiro | 13.9 | 956 |
| 21 | Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.10.006 . Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?. <i>European Urology</i> , 2021, 79, e113-e114. | 0.9 | 0 |
| 22 | Editorial: Standard and future in the treatment of renal cell carcinoma. <i>Current Opinion in Urology</i> , 2021, 31, 226-227. | 0.9 | 0 |
| 23 | Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 332-339. | 0.9 | 9 |
| 24 | Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4562-4562. | 0.8 | 2 |
| 25 | Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4576-4576. | 0.8 | 23 |
| 26 | The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor. <i>Journal of Neuro-Oncology</i> , 2021, 153, 497-505. | 1.4 | 4 |
| 27 | Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 764-773. | 0.8 | 14 |
| 28 | Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's™s Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2021;79:783-783. <i>European Urology</i> , 2021, 80, e145-e146. | 0.9 | 0 |
| 29 | Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242. | 3.4 | 13 |
| 30 | Changing the Course of an Orphan Disease. <i>New England Journal of Medicine</i> , 2021, 385, 2090-2091. | 13.9 | 0 |
| 31 | Impact of Patients's™ Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 88-94.e2. | 0.9 | 22 |
| 32 | Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e277-e283. | 0.9 | 5 |
| 33 | Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39. | 0.2 | 2 |
| 34 | Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852. | 2.0 | 18 |
| 35 | PD1/PD-L1 therapy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2020, 30, 534-541. | 0.9 | 8 |
| 36 | Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e588-e597. | 0.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020, 84, 101966. | 3.4 | 44 |
| 38 | Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S).. <i>Journal of Clinical Oncology</i> , 2020, 38, 687-687. | 0.8 | 11 |
| 39 | Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2020, 38, 690-690. | 0.8 | 3 |
| 40 | CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS772-TPS772. | 0.8 | 2 |
| 41 | Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2528-2528. | 0.8 | 0 |
| 42 | Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880. | 2.0 | 4 |
| 43 | Outcome with immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines.. <i>Journal of Clinical Oncology</i> , 2020, 38, 651-651. | 0.8 | 0 |
| 44 | Renal cell carcinoma treatment after first-line combinations. <i>Lancet Oncology</i> , The, 2019, 20, 1332-1334. | 5.1 | 8 |
| 45 | Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e957-e967. | 0.9 | 8 |
| 46 | Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e526-e533. | 0.9 | 9 |
| 47 | Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497. | 1.9 | 22 |
| 48 | Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. <i>Cancers</i> , 2019, 11, 422. | 1.7 | 45 |
| 49 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115. | 13.9 | 1,824 |
| 50 | Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?. <i>Annals of Translational Medicine</i> , 2019, 7, S275-S275. | 0.7 | 0 |
| 51 | Real-world experience with sunitinib treatment in patients with metastatic renal cell carcinoma: Clinical outcome according to risk score.. <i>Journal of Clinical Oncology</i> , 2019, 37, 606-606. | 0.8 | 4 |
| 52 | Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 173-179. | 0.6 | 19 |
| 53 | Individualized dosing with axitinib: rationale and practical guidance. <i>Future Oncology</i> , 2018, 14, 861-875. | 1.1 | 15 |
| 54 | HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. <i>Pathology and Oncology Research</i> , 2018, 24, 575-581. | 0.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 29-34. | 0.9 | 11 |
| 56 | Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 306-315. | 1.9 | 56 |
| 57 | Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764. | 0.8 | 43 |
| 58 | Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. <i>Haematologica</i> , 2018, 103, 1549-1556. | 1.7 | 95 |
| 59 | Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4574-4574. | 0.8 | 0 |
| 60 | Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4561-4561. | 0.8 | 0 |
| 61 | How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 227-233. | 1.1 | 18 |
| 62 | Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17009. | 18.1 | 1,727 |
| 63 | Metastasectomy for Metastatic Renal Cell Carcinoma (mRCC): Lucky Break or Evidence-Based Approach?. <i>Annals of Surgical Oncology</i> , 2017, 24, 308-310. | 0.7 | 0 |
| 64 | Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4594-TPS4594. | 0.8 | 15 |
| 65 | Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4570-4570. | 0.8 | 1 |
| 66 | Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. <i>BMC Cancer</i> , 2016, 16, 638. | 1.1 | 47 |
| 67 | Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. <i>Cancer Treatment Reviews</i> , 2016, 50, 109-117. | 3.4 | 64 |
| 68 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927. | 5.1 | 789 |
| 69 | Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4506-4506. | 0.8 | 1 |
| 70 | MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2016, 7, 78433-78447. | 0.8 | 45 |
| 71 | First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES. <i>Current Opinion in Urology</i> , 2015, 25, 395-401. | 0.9 | 8 |
| 72 | Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <sc>cM</sc>et as a negative prognostic factor. <i>Histopathology</i> , 2015, 67, 799-805. | 1.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies. <i>European Journal of Cancer</i> , 2015, 51, 2368-2374. | 1.3 | 20 |
| 74 | Individualized treatment schedule and investigator defined time to resistance (TTRi) may prolong survival in patients with metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2015, 33, e15585-e15585. | 0.8 | 0 |
| 75 | Third-line dovitinib in metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2014, 15, 245-246. | 5.1 | 12 |
| 76 | Improving Outcomes in Metastatic Clear Cell Renal Cell Carcinoma by Sequencing Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e228-e238. | 1.8 | 12 |
| 77 | Principal: A prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4600-TPS4600. | 0.8 | 0 |
| 78 | Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. <i>European Journal of Cancer</i> , Supplement, 2013, 11, 172-191. | 2.2 | 100 |
| 79 | Safety and efficacy of axitinib in pretreated patients with metastatic renal cell carcinoma: A single center experience of the Medical University of Vienna, Austria.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15535-e15535. | 0.8 | 2 |
| 80 | Patient and physician perspective on published therapy management recommendations for TKI-treated patients with a focus on sunitinib: The TheMaPaC project (Therapy Management Patient Consensus).. <i>Journal of Clinical Oncology</i> , 2013, 31, 445-445. | 0.8 | 1 |
| 81 | Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Preliminary results of a pooled analysis of noninterventional studies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 392-392. | 0.8 | 0 |
| 82 | Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 493-497. | 0.6 | 6 |
| 83 | Experience with sunitinib in the treatment of metastatic renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012, 4, 253-265. | 0.9 | 30 |
| 84 | Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2012, 19, 796-804. | 0.5 | 8 |
| 85 | Safety and efficacy of pazopanib in heavily pretreated and treatment-naïve patients with metastatic renal cell carcinoma (mRCC): A single center experience of the Medical University of Vienna, Austria.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15090-e15090. | 0.8 | 1 |
| 86 | CD98hc (SLC3A2), a novel biomarker correlating with grade of malignancy in renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15083-e15083. | 0.8 | 0 |
| 87 | Therapy Management Patient Consensus (TheMaPaC): A patient perspective on published therapy management recommendations for TKI-treated patients with a special focus on sunitinib.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19502-e19502. | 0.8 | 0 |
| 88 | Hypothyroidism in patients with renal cell carcinoma. <i>Cancer</i> , 2011, 117, 534-544. | 2.0 | 178 |
| 89 | Defining risk status in the first-line treatment of metastatic renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 961-968. | 1.2 | 6 |
| 90 | Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, 416-424. | 3.4 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. <i>Cancer Treatment Reviews</i> , 2009, 35, 289-296. | 3.4 | 20 |
| 92 | Management of cardiac adverse events occurring with sunitinib treatment. <i>Anticancer Research</i> , 2009, 29, 1627-9. | 0.5 | 7 |
| 93 | Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5204-5212. | 0.8 | 581 |